Countdown to Viatris (VTRS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Core Viewpoint - Analysts forecast a decline in Viatris' quarterly earnings and revenues, with earnings expected at $0.63 per share, a 16% decrease year-over-year, and revenues projected at $3.65 billion, down 2.8% from the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised 3.8% higher in the last 30 days, indicating a collective reevaluation by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Total net sales are expected to reach $3.64 billion, reflecting a 2.7% decrease from the year-ago quarter [5]. - Net sales in developed markets are projected at $2.20 billion, down 4.1% year-over-year [5]. - Emerging markets are expected to see net sales of $549.78 million, indicating a 3.1% increase compared to the previous year [5]. Specific Market Insights - Net sales for JANZ are anticipated at $302.56 million, a decline of 12.1% year-over-year [6]. - Greater China net sales are estimated at $578.59 million, reflecting a 3% increase [6]. - Other revenues are projected at $11.40 million, down 13.6% from the prior year [6]. Emerging Markets Breakdown - Net sales for emerging markets in generics are expected to reach $140.08 million, a 2% increase [7]. - Brands in emerging markets are projected at $409.75 million, indicating a 3.5% increase [7]. JANZ Market Breakdown - Net sales for JANZ generics are expected at $148.58 million, down 4.2% year-over-year [8]. - JANZ brands are projected at $148.32 million, reflecting a significant decline of 21.7% [8]. - Developed markets brands are expected to reach $1.22 billion, showing a slight decrease of 0.1% [8]. Overall Market Performance - Developed markets generics are projected at $1.02 billion, indicating a 5.5% decline year-over-year [9]. - Viatris shares have increased by 3.5% over the past month, outperforming the S&P 500 composite's 1% increase [9].